Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial
The aim of this phase III randomized clinical trial is to show PENTOCLO efficiency and its
tolerance in long survival patients irradiated before for cancer and presenting with partial
RIP of upper or lower legs.
We calculated to include 60 patients to show a significant clinical difference between the
two groups after 18 months of treatment: PENTOCLO [Pentoxifylline 400 (2x/d) + vitamine E
500 (2x/d) + intermittent Clodronate 800 (2/d, 5d/7)] versus triple placebo, with prednisone
20 (2d/7) for all patients.
RIP is assessed before treatment and every 6 months by a standardized sensory-motor
neurological (SOMA 95 modified by NCI-CTC 99) score used for main criteria at M18, and
various neurological scales of assessment (Visual Analog Scale [VAS] for pain / VAS for
paresthesia, Neuropathic Pain Symptom Inventory [NPSI], Overall Disability Sum Score [ODSS],
muscle testing, Nine hole peg test / Timed 25-Foot Walk), quality of life (SF36, Patient
Global Impression of Change and Clinical Global impression of Change [PGIC/ CGIC]) and
electrophysiology.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Sensory-motor neurological clinical assessment
Sensory-motor neurological clinical assessment of RIP patients as measured with SOMA scale (Subjective Objective Medical management Analytic involving tools) modified by NCI-CTC99 scale
18 months
No
Sylvie Delanian, MD, PhD
Principal Investigator
Oncologie-Radiothérapie, Hôpital Saint Louis , Paris, France
France: Ministry of Health
P081239
NCT01291433
March 2011
September 2015
Name | Location |
---|